Schnater J Marco, Aronson Daniël C, Plaschkes Jack, Perilongo Giorgio, Brown Julia, Otte Jean-Bernard, Brugieres Laurences, Czauderna Piotr, MacKinlay Gordon, Vos Anton
Pediatric Surgical Center Amsterdam (EKZ-AMC/VUmc), Amsterdam, The Netherlands.
Cancer. 2002 Feb 15;94(4):1111-20.
Surgical resection is the cornerstone of treatment for patients with hepatoblastoma (HB). The Society of Pediatric Oncology Liver Tumor Study Group launched its first prospective trial (SIOPEL-1) with the intention to treat all patients with preoperative chemotherapy and delayed surgical resection. The objective of this article was to assess the assumed surgical advantages of primary chemotherapy.
Between 1990 and 1994, 154 patients age < 16 years with HB were registered on SIOPEL-1. The pretreatment extent of disease was assessed, and, after undergoing biopsy, patients were treated with cisplatin 80 mg/m(2) intravenously over 24 hours and doxorubicin 60 mg/m(2) intravenously over 48 hours by continuous infusion (PLADO). Generally, tumors were resected after four of a total of six courses of PLADO.
One hundred twenty eight patients underwent surgical resection (13 patients underwent primary surgery, and 115 patients underwent delayed surgery after PLADO). A pretreatment surgical biopsy was performed in 96 of 128 patients (75%). Biopsy complications occurred in 7 of 96 patients (7%). Twenty-two patients showed pulmonary metastases at the time of diagnosis, and 7 patients underwent thoracotomy. Operative morbidity and mortality were 18% and 5%, respectively. Complete macroscopic surgical resection was achieved in 106 patients (92%), including 6 patients who underwent orthotopic liver transplantation. The actuarial 5-year event free survival (EFS) rate for all 154 patients in the study was 66%, and the overall survival (OS) rate was 75%. For the 115 patients who were included in the surgical analysis that followed the exact protocol, the EFS and OS rates were 75% and 85%, respectively.
Biopsy is a safe procedure and should be performed routinely. Preoperative chemotherapy seems to make tumor resection easier. Reresection of a positive resection margin does not necessarily have to be performed, because postoperative chemotherapy showed good results. Resection of lung metastases can be curative if there is local control of the primary tumor; however, results showed that the patient's prognosis was worse. Surgical morbidity or mortality rates were not necessarily higher in large multicenter studies. More importantly, countries of lesser economic status also can contribute effectively to these trials.
手术切除是肝母细胞瘤(HB)患者治疗的基石。小儿肿瘤学会肝脏肿瘤研究组开展了其首个前瞻性试验(SIOPEL - 1),旨在对所有患者进行术前化疗并延迟手术切除。本文的目的是评估原发性化疗假定的手术优势。
1990年至1994年间,154例年龄小于16岁的HB患者登记参加SIOPEL - 1。评估疾病的预处理范围,活检后,患者接受顺铂80mg/m²静脉滴注24小时和阿霉素60mg/m²持续静脉滴注48小时(PLADO)治疗。一般来说,在总共六个疗程的PLADO中的四个疗程后进行肿瘤切除。
128例患者接受了手术切除(13例患者接受一期手术,115例患者在PLADO后接受延迟手术)。128例患者中有96例(75%)进行了术前手术活检。96例患者中有7例(7%)发生活检并发症。22例患者在诊断时出现肺转移,7例患者接受了开胸手术。手术发病率和死亡率分别为18%和5%。106例患者(92%)实现了完全宏观手术切除,其中6例患者接受了原位肝移植。该研究中所有154例患者的精算5年无事件生存率(EFS)为66%,总生存率(OS)为75%。对于按照确切方案纳入手术分析的115例患者,EFS和OS率分别为75%和85%。
活检是一种安全的操作,应常规进行。术前化疗似乎使肿瘤切除更容易。阳性切缘不一定必须再次切除,因为术后化疗显示出良好效果。如果原发肿瘤得到局部控制,肺转移瘤切除可以治愈;然而,结果显示患者预后较差。在大型多中心研究中,手术发病率或死亡率不一定更高。更重要的是,经济状况较差的国家也可以有效地为这些试验做出贡献。